Akèy › Lukemi lenfositè kwonik › Ohio › Columbus
Etid klinik pou Lukemi lenfositè kwonik nan Columbus, OH
28 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- ak 8 plis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- ak 8 plis
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Ap rekriteFaz 3
- Study Site 104, Columbus
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- The Ohio State University, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
- Research Site, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 1
- The James Cancer Hospital and Solove Research Institute, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Ap rekriteFaz 3
- OSU Comprehensive Cancer Center, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Ap rekriteFaz 1
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- The Ohio State University, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Ohio State University Comprehensive Cancer Center, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 2
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Ap rekriteFaz 2
- The Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
HPC Offered for PRESERVE Expansion
Ap rekriteEtid obsèvasyon
- The Ohio State University Medical Center, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
- Nashville, TN13 etid
Lòt etid nan Columbus
- Kansè Poumon ki pa ti selil56 etid
- Kansè nan tete39 etid
- Kansè ovè39 etid
- Kansè (tout kalite)38 etid
- Kansè poumon37 etid
- Leksemi mieloïd egi35 etid
- Kansè Metastatik27 etid
- Kansè Endomèt25 etid
- Kansè kolorektal24 etid
- Kansè pwostat24 etid
- Myelom Miltip24 etid
- Melanom21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.